Education
About Us
Working with TipRanks
Follow Us
DBV Technologies SA - American (DBVT)
NASDAQ:DBVT
DBVT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.20 - $16.98
Previous CloseN/A
Volume52.91K
Average Volume (3M)82.46K
Market Cap
$446.31M
Enterprise Value$121.25M
Total Cash (Recent Filing)$103.21M
Total Debt (Recent Filing)$14.59M
Price to Earnings (P/E)―
Beta0.09
Next Earnings
Oct 29, 2025EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding29,702,724
10 Day Avg. Volume176,907
30 Day Avg. Volume82,460
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.27
Enterprise Value/Revenue76.60
Enterprise Value/Gross Profit-16.14
Enterprise Value/Ebitda-1.05
Forecast
1Y Price Target
$18.67Price Target Upside24.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Efficacy Of ProductThe Viaskin Peanut patch for toddlers showed compelling efficacy and durability in the EPITOPE trial, with a significant percentage of toddlers meeting responder criteria after 12 months.
Market ExpansionViaskin Peanut has the potential to dramatically expand the market of children who undergo treatment for peanut allergies.
Regulatory ApprovalFDA has formalized the Accelerated Approval pathway for the Viaskin Peanut patch, which could streamline the regulatory process.
Bears Say
Financial ConstraintsDBV's current cash balance of $103.2M is expected to fund operations.
Market CompetitionOmalizumab biosimilars are expected to become widely available, which may reduce constraints on coverage/reimbursement of a branded agent.
Product PricingViaskin Peanut is expected to be priced lower than omalizumab biosimilars, likely lowering the barrier for adolescents.
DBV Technologies SA - American News
DBVT FAQ
What was DBV Technologies SA - American’s price range in the past 12 months?
DBV Technologies SA - American lowest stock price was $2.20 and its highest was $16.98 in the past 12 months.
What is DBV Technologies SA - American’s market cap?
DBV Technologies SA - American’s market cap is $446.31M.
When is DBV Technologies SA - American’s upcoming earnings report date?
DBV Technologies SA - American’s upcoming earnings report date is Oct 29, 2025 which is in 15 days.
How were DBV Technologies SA - American’s earnings last quarter?
DBV Technologies SA - American released its earnings results on Jul 29, 2025. The company reported -$0.31 earnings per share for the quarter, missing the consensus estimate of -$0.18 by -$0.13.
Is DBV Technologies SA - American overvalued?
According to Wall Street analysts DBV Technologies SA - American’s price is currently Undervalued.
Does DBV Technologies SA - American pay dividends?
DBV Technologies SA - American does not currently pay dividends.
What is DBV Technologies SA - American’s EPS estimate?
DBV Technologies SA - American’s EPS estimate is -0.32.
How many shares outstanding does DBV Technologies SA - American have?
DBV Technologies SA - American has 29,702,724 shares outstanding.
What happened to DBV Technologies SA - American’s price movement after its last earnings report?
DBV Technologies SA - American reported an EPS of -$0.31 in its last earnings report, missing expectations of -$0.18. Following the earnings report the stock price went down -4.082%.
Which hedge fund is a major shareholder of DBV Technologies SA - American?
Currently, no hedge funds are holding shares in DBVT
DBV Technologies SA - American Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.67 (24.47% Upside)
$18.67 (24.47% Upside)
Blogger Sentiment
Bearish
DBVT Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $1.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 8.0%
Last 30 Days ▼ 8.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
322.89%
12-Months-Change
Fundamentals
Return on Equity
-148.53%
Trailing 12-Months
Asset Growth
25.61%
Trailing 12-Months
Company Description
DBV Technologies SA - American
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
DBVT Stock 12 Month Forecast
Average Price Target
$18.67
▲(24.47% Upside)
Technical Analysis
Larimar Therapeutics
―
Korro Bio
―
4D Molecular Therapeutics
―
PureTech Health
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
0.81% Insiders
0.02% Mutual Funds
10.88% Other Institutional Investors
88.30% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---